Good News | Microread Genetics' Fragile X Product Successfully Passes Russian RZN On-site Quality System Inspection

BEIJING — Beijing Microread Genetics Co., Ltd. has cleared a major regulatory hurdle in its push into Eurasian markets, passing a three-day on-site quality system inspection by Russia's Federal Service for Surveillance in Healthcare (RZN) with zero major defects.

The inspection, conducted from June 16 to June 18, 2026, focused on the company's Fragile X Syndrome FMR1 Gene Detection Kit—a diagnostic product targeting a rare genetic disorder. Russian regulators benchmarked their review against ISO 13485 international quality standards and Russia's domestic medical device access requirements, scrutinizing six core areas: research and development traceability, production controls in a Class 100,000 molecular clean room, end-to-end quality management, cross-border stability verification, Russian-language compliance documentation, and supply chain quality control.

The one-time pass represents a critical milestone in Microread Genetics' international expansion strategy. The company's R&D, production, quality, regulatory affairs, logistics, and technical service teams coordinated throughout the inspection, fielding questions and providing documentation on demand.

Russian inspectors highlighted three core strengths of the Chinese diagnostics company. First, Microread's proprietary Fragile X detection technology aligns with the screening needs of Commonwealth of Independent States populations, with diagnostic accuracy meeting Russian clinical standards. Second, the company has established an integrated domestic and international quality management system with closed-loop processes and fully traceable records—satisfying Russia's stringent requirements for overseas in vitro diagnostics manufacturers. Third, the company's R&D-production-quality coordination mechanism is mature, demonstrating capacity for scaled, stable supply and cross-border contract fulfillment.

The successful inspection clears the path for Microread Genetics to obtain official Russian registration for its Fragile X detection product, opening market access across the Eurasian Economic Union. This move fills a gap in the Russian market for domestically produced reproductive and genetic rare disease diagnostic reagents, while expanding the company's overseas commercialization channels.

For China's in vitro diagnostics industry, the achievement signals that domestic quality systems and R&D capabilities can meet first-tier international regulatory standards—potentially serving as a compliance benchmark for other Chinese IVD companies seeking entry into Commonwealth markets.

Microread Genetics said it will continue advancing the registration process, refining its quality management systems, and deepening its focus on precision reproductive and genetic diagnostics as it pushes its innovative diagnostic products onto the global stage.